D. Nash

发表

Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma.

A. Ebens, C. Noland, J. Lyssikatos, 2019, Journal of medicinal chemistry.

Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders.

K. Thewlis, E. Chiarparin, Christopher N. Johnson, 2011, Bioorganic & medicinal chemistry letters.

Heterocyclic analogues of 2-aminotetralins with high affinity and selectivity for the dopamine D3 receptor.

G. Riley, G. Stemp, K. Y. Avenell, 1999, Bioorganic & medicinal chemistry letters.

Fused aminotetralins: novel antagonists with high selectivity for the dopamine D3 receptor.

K. Thewlis, G. Riley, G. Stemp, 1998, Bioorganic & medicinal chemistry letters.

2-[(substituted)phenyl]-5-[1-(2-phenylazacycloheptyl)methyl]-1H-pyrroles with high affinity and selectivity for the dopamine D3 receptor

G. Riley, Stephen A. Smith, Christopher N. Johnson, 1997 .

Novel 2,5-disubstituted-1H-pyrroles with high affinity for the dopamine D3 receptor : N-benzyl modifications

G. Riley, Stephen A. Smith, Christopher N. Johnson, 1997 .

Novel 2,5-disubstituted-1H-pyrroles with high affinity for the dopamine D3 receptor

G. Riley, Christopher N. Johnson, G. Stemp, 1996 .

N-(SUBSTITUTED-PHENYL) PIPERAZINES : ANTAGONISTS WITH HIGH BINDING AND FUNCTIONAL SELECTIVITY FOR DOPAMINE D4 RECEPTORS

G. Riley, Stephen A. Smith, G. Stemp, 1996 .

Design and synthesis of novel 2,3-dihydro-1H-isoindoles with high affinity and selectivity for the dopamine D3 receptor.

G. Macdonald, K. Thewlis, G. Riley, 2001, Bioorganic & Medicinal Chemistry Letters.

Heterocyclic analogues of 2-aminotetralins with high affinity and selectivity for the dopamine D3 receptor.

G. Riley, G. Stemp, K. Y. Avenell, 1999, Bioorganic & medicinal chemistry letters.

Novel 1,2,3,4-tetrahydroisoquinolines with high affinity and selectivity for the dopamine D3 receptor.

K. Thewlis, G. Riley, G. Stemp, 1999, Bioorganic & medicinal chemistry letters.

Synthesis and antihypertensive activity of 4-(cyclic amido)-2H-1-benzopyrans.

T. Hamilton, R. Buckingham, G. Stemp, 1986, Journal of medicinal chemistry.

The synthesis, and dopamine D2 and serotonin 5-HT3 receptor affinity of 3-aza analogues (pyridyl) of 4-amino-5-chloro-2-methoxybenzamides

F. King, J. Jerman, M. Coldwell, 1995 .

The identification of a novel renin inhibitor of equivalent efficacy following oral or intravenous administration.

P. Ham, Stephen A. Smith, R. Buckingham, 1994 .

Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.

J. Hagan, D. Middlemiss, K. Thewlis, 2000, The Journal of pharmacology and experimental therapeutics.

Probing Mechanisms of CYP3A Time-Dependent Inhibition Using a Truncated Model System.

J. Lyssikatos, Suzanne Tay, P. Fan, 2015, ACS medicinal chemistry letters.

The identification of structurally novel, selective, orally bioavailable positive modulators of mGluR2.

Paul W Smith, Emma L. Koppe, C. Corti, 2010, Bioorganic & medicinal chemistry letters.

Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat.

J. Hagan, D. Middlemiss, K. Thewlis, 2000, Journal of medicinal chemistry.

Evidence for antagonist activity of the dopamine D3 receptor partial agonist, BP 897, at human dopamine D3 receptor.

G. Riley, M. Wood, K. Y. Avenell, 2000, European journal of pharmacology.

Design and synthesis of 2-naphthoate esters as selective dopamine D4 antagonists.

J. Hagan, D. Middlemiss, G. Riley, 1996, Journal of medicinal chemistry.

Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist.

J. Hagan, G. Macdonald, D. Middlemiss, 2003, Journal of medicinal chemistry.

Probing Mechanisms of CYP3A Time-Dependent Inhibition Using a Truncated Model System.

J. Lyssikatos, Suzanne Tay, P. Fan, 2015, ACS medicinal chemistry letters.